Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept Liver Disease Strategy Bets Heavily On New Surrogate Endpoints

Executive Summary

Intercept is aiming to file obeticholic acid for accelerated approval in two liver disease indications and is mining clinical outcomes data to support new surrogate endpoints with the help of a clinical network dubbed the “Supergroup.”

Advertisement

Related Content

Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint
Searching For Surrogate Endpoints Requires Teamwork

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel